InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,027.04
(
-0.88%
)
US TECH 100
16,872.00
(
-1.10%
)
Dow Jones
37,983.40
(
-1.24%
)
Brent Oil
86.85
(
-0.42%
)
Bitcoin
64,149.72
(
-0.20%
)
Post# of 251596
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: IanFromSI post# 181532

Friday, 08/29/2014 3:25:19 AM

Friday, August 29, 2014 3:25:19 AM

Post# of 251596
BIIB033 anti-LINGO-1 phase I data

No reason to be disappointed yet Ian, MS patients only got two doses of BIIB033 in the phase I trial. We should wait for data from the following phase II trials (first to report is the one in AON and much later the MS trial), to discuss efficacy.

http://clinicaltrials.gov/ct2/show/NCT01721161?term=NCT01721161&rank=1

http://clinicaltrials.gov/ct2/show/NCT01864148?term=NCT01864148&rank=1
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up